Nykode Therapeutics AS (OTCMKTS:VACBF – Get Free Report) was the recipient of a large drop in short interest in February. As of February 27th, there was short interest totaling 1,059,580 shares, a drop of 14.2% from the February 12th total of 1,235,218 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Nykode Therapeutics AS Price Performance
Shares of OTCMKTS:VACBF opened at $0.38 on Tuesday. The business’s 50-day moving average is $0.30 and its 200 day moving average is $0.23. Nykode Therapeutics AS has a 1 year low of $0.16 and a 1 year high of $0.38.
About Nykode Therapeutics AS
Nykode Therapeutics AS (OTCMKTS:VACBF) is a clinical-stage biotechnology company based in Oslo, Norway, focused on the development of precisely targeted immunotherapies. The company’s proprietary platform is designed to deliver antigenic payloads directly to antigen-presenting cells, with the goal of eliciting potent and durable immune responses against both cancerous and infectious disease targets. By combining modular antigen design with novel delivery modalities, Nykode aims to drive next-generation vaccine and immunotherapy solutions.
The company’s clinical pipeline includes several lead candidates in oncology and infectious diseases.
Featured Stories
- Five stocks we like better than Nykode Therapeutics AS
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Nykode Therapeutics AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nykode Therapeutics AS and related companies with MarketBeat.com's FREE daily email newsletter.
